Tejnaksh Healthcare FY26 profit falls 47% on lower revenue
Tejnaksh Healthcare reported a 47.4% decline in consolidated net profit to ₹118.11 lakh for FY26, driven by a 16.3% drop in revenue to ₹1,078.69 lakh. The Board approved the audited results and decided not to proceed with the proposed Rights Issue due to postponed expansion plans.
*this image is generated using AI for illustrative purposes only.
Tejnaksh Healthcare Limited reported a 47.4% decline in consolidated net profit to ₹118.11 lakh for the financial year ended March 31, 2026, as revenue from operations fell 16.3% to ₹1,078.69 lakh. The company's total income for the year stood at ₹1,117.99 lakh, compared to ₹1,330.14 lakh in the previous year. The Board of Directors approved the audited financial results for the standalone and consolidated entities for the quarter and year ended March 31, 2026.
The statutory auditors, M/s Maheshwari and Co, issued an unmodified opinion on the annual financial results. The consolidated financial results include the performance of the subsidiary, Tejvedaant Healthcare Private Limited. For the quarter ended March 31, 2026, the company reported a profit of ₹34.86 lakh, a decrease from ₹42.33 lakh in the corresponding quarter of the previous year.
Financial Performance
The company's expenses for the year totaled ₹953.37 lakh, a reduction from ₹1,011.00 lakh in the prior year. Profit before tax for the year stood at ₹164.62 lakh, significantly lower than the ₹319.14 lakh reported in FY25. The basic and diluted earnings per share (EPS) for the year declined to ₹0.61 from ₹1.15 in the previous year.
Consolidated Financial Results (Year Ended March 31, 2026)
| Particulars | Year Ended Mar-26 (₹ in lakh) | Year Ended Mar-25 (₹ in lakh) |
|---|---|---|
| Revenue from operations (net) | 1,078.69 | 1,289.71 |
| Total Income | 1,117.99 | 1,330.14 |
| Total Expenses | 953.37 | 1,011.00 |
| Profit for the period | 118.11 | 223.05 |
| Earnings Per Share (EPS) | 0.61 | 1.15 |
Board Decisions
The Board discussed the proposed offer of shares via Rights Issue and decided not to proceed further with the issue, citing the postponement of the company's expansion plans. Additionally, the Board re-appointed M/s Kapil Tulsani & Associates as the Internal Auditor for the period commencing April 1, 2026, and ending March 31, 2027.
Dr. Ashish V. Rawandale, Managing Director, was authorized to sign and submit requisite forms with the Registrar of Companies for the financial years 2026-2027. The company noted that the New Labour Codes, effective from November 21, 2025, led to a remeasurement of gratuity liability, resulting in a reversal recognized as Other Income in the current reporting period.
Historical Stock Returns for Tejnaksh Healthcare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -6.61% | -10.69% | -17.62% | -14.27% | -37.44% | -79.13% |
What specific factors led to the 16.3% decline in revenue, and are these headwinds expected to persist into FY27?
How will the decision to postpone expansion plans impact the company's long-term growth strategy and market competitiveness?
With the Rights Issue cancelled, what alternative funding sources will the company utilize to support operations or future expansion?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
